Brought to you by:

Ambrosia Biosciences

Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.

weight loss GLP-1
Biotech

Ambrosia scores $100M series B to advance next-gen oral GLP-1

Ambrosia Biosciences is aiming to initiate a trial for its oral small-molecule GLP-1 therapy, backed by an oversubscribed $100 million series B round.
Will Maddox Mar 31, 2026 10:02am

Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders